Managing ADHD in Adults: A Growing Primary Care Responsibility
Check out our extensive video library (see channel for our latest videos)
Abstract
Adult attention-deficit/hyperactivity disorder (ADHD) presents significant challenges for primary care practitioners, with prevalence rates of 4-5% among adults worldwide. This comprehensive analysis examines the evolving role of primary care physicians in diagnosing and managing adult ADHD, addressing the clinical complexities, diagnostic uncertainties, and treatment paradigms that characterize this neurodevelopmental disorder. Through systematic review of current evidence and clinical practice guidelines, this paper demonstrates that primary care providers can effectively manage adult ADHD when equipped with appropriate assessment tools, treatment protocols, and ongoing monitoring strategies. Key findings indicate that systematic approaches to screening, evidence-based pharmacological interventions, and coordinated care models significantly improve patient outcomes while addressing healthcare accessibility challenges. The analysis encompasses diagnostic methodologies, pharmacotherapeutic considerations, comorbidity management, and long-term care coordination within primary care frameworks. Implications for practice include the necessity for enhanced provider education, standardized assessment protocols, and integrated care delivery models that optimize resource utilization while maintaining clinical effectiveness.
Introduction
The recognition of attention-deficit/hyperactivity disorder (ADHD) as a persistent neurodevelopmental condition extending into adulthood represents a paradigmatic shift in contemporary medical understanding. Historical conceptualizations of ADHD as a childhood-limited disorder have been superseded by longitudinal research demonstrating symptom persistence in approximately 60% of affected children, resulting in an estimated adult prevalence of 4-5% globally (Faraone et al., 2015). This epidemiological reality has profound implications for primary care practice, positioning family physicians, internists, and other primary care providers as frontline clinicians in the identification, diagnosis, and management of adult ADHD.
The neurobiological underpinnings of ADHD involve dysregulation of dopaminergic and noradrenergic neurotransmitter systems, particularly within prefrontal cortical circuits responsible for executive functioning, attention regulation, and behavioral inhibition (Cortese et al., 2012). These neurochemical alterations manifest as persistent patterns of inattention, hyperactivity, and impulsivity that significantly impair academic, occupational, and social functioning across developmental stages.
Primary care physicians occupy a unique position within the healthcare delivery system, serving as initial points of contact for adults experiencing attention-related difficulties. This role carries both opportunities and challenges, as primary care settings must balance comprehensive patient care with time constraints, resource limitations, and varying levels of provider expertise in psychiatric disorders. The increasing prevalence of adult ADHD diagnoses, coupled with limited availability of psychiatric specialists in many regions, necessitates enhanced primary care capacity for managing this condition.
The clinical presentation of adult ADHD differs substantially from childhood manifestations, requiring nuanced understanding of developmental trajectories and symptomatic evolution. While hyperactive behaviors often attenuate with age, attentional deficits and executive dysfunction frequently persist or may become more apparent as environmental demands increase. Adults with ADHD commonly present with complaints of chronic disorganization, procrastination, time management difficulties, and relationship problems rather than the overt behavioral disruptions characteristic of childhood presentations.
Diagnostic challenges in adult ADHD are compounded by retrospective symptom reporting requirements, potential overlap with other psychiatric conditions, and the absence of definitive biological markers. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria require evidence of symptom onset before age 12, creating diagnostic complexity when childhood history is unclear or unavailable. Additionally, comorbid conditions including mood disorders, anxiety disorders, and substance use disorders occur in the majority of adults with ADHD, necessitating comprehensive differential diagnosis and integrated treatment approaches.
The economic and social burden of untreated adult ADHD is substantial, with documented impacts on occupational performance, interpersonal relationships, and healthcare utilization. Adults with ADHD demonstrate higher rates of job instability, academic underachievement, motor vehicle accidents, and psychiatric comorbidity compared to the general population (Biederman et al., 2006). These outcomes underscore the importance of timely identification and evidence-based treatment within accessible healthcare settings.
This analysis examines the current state of adult ADHD management in primary care, evaluating diagnostic methodologies, treatment approaches, and care delivery models. The objectives include providing evidence-based recommendations for primary care practitioners, identifying system-level barriers to optimal care, and proposing strategies for enhancing clinical outcomes while maintaining feasibility within primary care frameworks.
Neurobiological Foundations and Clinical Phenomenology
Adult ADHD represents a complex neurodevelopmental disorder characterized by persistent alterations in brain structure and function that affect attention regulation, executive control, and behavioral inhibition. Neuroimaging studies demonstrate consistent patterns of reduced activity and connectivity within fronto-striatal circuits, particularly involving the prefrontal cortex, anterior cingulate cortex, and basal ganglia structures (Cortese et al., 2012). These neural networks are fundamental to cognitive control processes including working memory, inhibitory control, and attention allocation.
The dopaminergic and noradrenergic neurotransmitter systems play central roles in ADHD pathophysiology. Dopaminergic dysfunction within mesocortical and mesolimbic pathways contributes to attention deficits and motivational abnormalities, while noradrenergic system alterations affect arousal regulation and cognitive flexibility. These neurochemical imbalances form the theoretical basis for pharmacological interventions targeting monoaminergic neurotransmission.
Genetic factors contribute significantly to ADHD susceptibility, with heritability estimates ranging from 70-80% based on twin studies. Multiple candidate genes have been identified, including those encoding dopamine receptors (DRD4, DRD2), dopamine transporter (DAT1), and norepinephrine transporter (NET1), though individual effect sizes remain modest. Genome-wide association studies continue to elucidate the polygenic architecture underlying ADHD vulnerability.
The clinical phenomenology of adult ADHD encompasses three primary symptom domains: inattention, hyperactivity, and impulsivity, as defined by DSM-5 criteria. However, the manifestation of these symptoms evolves significantly from childhood to adulthood, requiring developmental perspective in clinical assessment. Inattentive symptoms in adults typically present as difficulty sustaining attention during lengthy tasks, frequent mental fatigue, and challenges with detail-oriented activities. Organizational difficulties, procrastination, and time management problems are common manifestations that significantly impact occupational and academic functioning.
Hyperactivity symptoms in adults often manifest as internal restlessness rather than overt motor activity. Adults may report feeling “driven by a motor” or experiencing difficulty relaxing, but are less likely to display the physical restlessness characteristic of childhood presentations. This internalization of hyperactive symptoms contributes to diagnostic challenges and potential underrecognition.
Impulsivity in adults encompasses cognitive, behavioral, and emotional dimensions. Cognitive impulsivity involves hasty decision-making without adequate consideration of consequences. Behavioral impulsivity manifests as interrupting others, difficulty waiting in lines, or making spontaneous purchases. Emotional impulsivity, sometimes termed emotional dysregulation, involves intense emotional reactions and difficulty modulating affective responses.
Executive function deficits represent a core feature of adult ADHD that significantly impacts daily functioning. These include working memory impairments affecting the ability to hold and manipulate information mentally, inhibitory control deficits leading to difficulty suppressing inappropriate responses, and cognitive flexibility problems resulting in rigid thinking patterns and difficulty adapting to changing situations.
The heterogeneity of adult ADHD presentations necessitates recognition of three presentation specifiers: predominantly inattentive presentation, predominantly hyperactive-impulsive presentation, and combined presentation. The inattentive presentation is particularly common among adults, especially women, and may be overlooked due to less disruptive external behaviors.
Functional impairment assessment is crucial for establishing clinical significance, as DSM-5 requires evidence of functional impairment in two or more settings. Adults with ADHD commonly experience difficulties in occupational settings, including problems with task completion, meeting deadlines, and maintaining productivity. Academic impairments may persist into higher education or professional development contexts. Social and interpersonal relationships are frequently affected by attention problems, forgetfulness, and emotional dysregulation.
The course of ADHD symptoms across the lifespan demonstrates both continuity and change. While hyperactive symptoms often diminish with age, attention problems and executive dysfunction typically persist. Some individuals may experience symptom exacerbation during periods of increased stress or life transitions. Conversely, structured environments or personally engaging activities may partially ameliorate symptoms, contributing to variability in functional outcomes.
Epidemiological Considerations and Risk Factors 
The epidemiology of adult ADHD has evolved significantly as diagnostic awareness has increased and longitudinal studies have documented symptom persistence from childhood. Current estimates indicate a global adult prevalence of approximately 4-5%, with some variation across geographic regions and cultural contexts (Faraone et al., 2015). These prevalence rates represent a substantial public health burden, affecting millions of adults worldwide.
Gender differences in adult ADHD prevalence and presentation patterns have important clinical implications. Historically, ADHD was considered predominantly a male disorder, with childhood diagnosis rates favoring boys by ratios of 3:1 to 9:1. However, adult prevalence rates demonstrate more balanced gender distributions, suggesting systematic underdiagnosis of girls and women. Female presentations often involve predominantly inattentive symptoms that may be less disruptive and thus less likely to trigger clinical attention.
Age-related patterns in ADHD diagnosis and treatment seeking reflect both developmental factors and changing clinical awareness. Many adults receive their first ADHD diagnosis in their 20s, 30s, or even later, often prompted by their children’s ADHD evaluations or increasing life demands that overwhelm compensatory strategies. This delayed recognition contributes to years of untreated symptoms and associated functional impairments.
Socioeconomic factors influence both ADHD prevalence and access to care. Adults from lower socioeconomic backgrounds may have higher rates of undiagnosed ADHD due to limited access to healthcare services during childhood. Additionally, the cognitive and organizational challenges associated with ADHD may contribute to educational and occupational underachievement, creating cyclical patterns of disadvantage.
Cultural and ethnic disparities in ADHD diagnosis and treatment represent ongoing concerns for equitable healthcare delivery. Research suggests that African American and Hispanic adults are less likely to receive ADHD diagnoses compared to Caucasian adults, even when symptom severity appears similar. These disparities may reflect cultural differences in symptom interpretation, healthcare access barriers, or provider biases in diagnostic practices.
Risk factors for adult ADHD include both genetic and environmental influences. Family history of ADHD significantly increases risk, with first-degree relatives showing 4-5 fold increased prevalence rates. Prenatal and perinatal risk factors include maternal substance use, premature birth, and low birth weight. Environmental exposures such as lead contamination and psychosocial adversity may also contribute to ADHD development.
Comorbidity patterns in adult ADHD are extensive and clinically significant. Mood disorders, particularly depression and bipolar disorder, co-occur in 50-70% of adults with ADHD. Anxiety disorders affect approximately 40-60% of adults with ADHD. Substance use disorders occur at rates 2-3 times higher than in the general population, often representing attempts at self-medication or secondary consequences of impulsivity and emotional dysregulation.
The relationship between ADHD and substance use disorders deserves particular attention given its implications for treatment planning. Adults with ADHD are at increased risk for alcohol use disorders, cannabis dependence, and stimulant abuse. Nicotine dependence rates are especially elevated, with smoking rates 2-3 times higher than population norms. These patterns necessitate comprehensive substance use assessment and integrated treatment approaches.
Sleep disorders frequently co-occur with adult ADHD, affecting 50-70% of individuals. Common sleep problems include delayed sleep phase syndrome, restless leg syndrome, and sleep-disordered breathing. The bidirectional relationship between sleep disturbances and ADHD symptoms complicates treatment planning and may require coordinated interventions.
Advanced Diagnostic Methodologies
The diagnosis of adult ADHD requires sophisticated clinical assessment approaches that address the unique challenges of retrospective symptom reporting, symptom overlap with other conditions, and the absence of definitive biomarkers. Contemporary diagnostic frameworks emphasize multi-modal assessment strategies incorporating standardized instruments, structured interviews, and comprehensive functional evaluation.
The DSM-5 diagnostic criteria for ADHD require evidence of persistent inattentive and/or hyperactive-impulsive symptoms that began before age 12, cause functional impairment in multiple settings, and are not better explained by other mental disorders. For adults, the threshold for diagnosis was reduced from six to five symptoms in either domain, acknowledging developmental changes in symptom expression. This modification reflects recognition that symptom severity may diminish with age while still causing clinically significant impairment.
Structured diagnostic interviews represent the gold standard for adult ADHD assessment. The Conners Adult ADHD Diagnostic Interview for DSM-IV (CAADID) provides systematic evaluation of current and childhood symptoms, functional impairment, and differential diagnosis. The Adult ADHD Clinical Diagnostic Scale (ACDS) offers another validated interview format with demonstrated reliability and validity. These instruments require substantial time investment but provide comprehensive diagnostic information.
Self-report rating scales offer efficient screening and symptom assessment tools suitable for primary care settings. The Adult ADHD Self-Report Scale (ASRS) is widely used and demonstrates good psychometric properties. The 18-item version provides comprehensive symptom assessment, while the 6-item screener offers rapid initial evaluation. The Conners Adult ADHD Rating Scales include both self-report and observer versions, enabling collection of collateral information when available.
Observer ratings from family members, partners, or close friends can provide valuable external perspectives on symptom severity and functional impact. The Adult ADHD Investigator Symptom Rating Scale includes observer versions specifically designed for this purpose. However, observer availability and willingness to participate may limit the feasibility of this approach in some cases.
Childhood symptom documentation presents significant challenges in adult ADHD diagnosis. Retrospective self-report of childhood symptoms may be unreliable due to memory limitations and potential bias. When available, school records, report cards, and standardized test scores can provide objective evidence of childhood difficulties. The Wender Utah Rating Scale (WURS) attempts to systematically assess retrospective childhood symptoms but has limitations in reliability and validity.
Cognitive testing and neuropsychological assessment are sometimes employed in adult ADHD evaluation, though their role remains controversial. Continuous performance tests (CPTs) measure sustained attention and response inhibition but show substantial overlap between ADHD and non-ADHD populations. Comprehensive neuropsychological batteries may identify executive function deficits but cannot definitively diagnose ADHD due to significant individual variability and overlap with other conditions.
Functional impairment assessment is essential for establishing clinical significance and treatment planning. The Weiss Functional Impairment Rating Scale-Adult (WFIRS-A) provides systematic evaluation of impairment across multiple life domains including family, work, school, and social relationships. The Barkley Functional Impairment Scale offers another validated approach to functional assessment.
Differential diagnosis considerations are crucial given symptom overlap between ADHD and other psychiatric conditions. Mood disorders, particularly depression and bipolar disorder, can cause attention problems and cognitive difficulties. Anxiety disorders may present with concentration difficulties and restlessness. Substance use disorders can produce attention problems and behavioral dysregulation. Sleep disorders, thyroid dysfunction, and other medical conditions should be considered in the differential diagnosis.
Technology-enhanced assessment approaches are emerging as potential tools for improving diagnostic accuracy and efficiency. Computerized assessment batteries can provide standardized administration and scoring while reducing clinician time requirements. Virtual reality-based attention tasks may offer more ecologically valid assessment of attention problems. However, these technologies require further validation before routine clinical implementation.
Biomarker research continues to explore potential biological indicators of ADHD, including neuroimaging findings, neurotransmitter metabolites, and genetic markers. While these approaches show promise for understanding ADHD pathophysiology, none currently provide clinically applicable diagnostic tests. Future developments in precision medicine may eventually enable more objective diagnostic approaches.
The assessment process should also include evaluation for common comorbid conditions given their high prevalence and impact on treatment planning. Standardized screening instruments for depression (PHQ-9), anxiety (GAD-7), and substance use disorders (AUDIT, DAST) can efficiently identify co-occurring conditions requiring integrated treatment approaches.
Evidence-Based Treatment Paradigms
The treatment of adult ADHD encompasses multiple therapeutic modalities, with pharmacological interventions serving as the primary evidence-based approach. Treatment selection requires consideration of symptom severity, functional impairment patterns, comorbid conditions, patient preferences, and practical factors such as medication access and cost considerations.
Stimulant medications remain the first-line pharmacological treatment for adult ADHD, with extensive research demonstrating efficacy and safety. Methylphenidate-based medications include immediate-release formulations (Ritalin, Methylin) and extended-release preparations (Concerta, Ritalin LA, Metadate CD). Amphetamine-based stimulants include immediate-release (Adderall) and extended-release formulations (Adderall XR, Vyvanse). These medications demonstrate comparable efficacy, with response rates of approximately 70% in controlled trials.
The mechanism of action for stimulant medications involves inhibition of dopamine and norepinephrine reuptake, increasing synaptic concentrations of these neurotransmitters in prefrontal cortical regions. This neurochemical enhancement improves attention regulation, working memory function, and behavioral inhibition. The therapeutic effects are typically apparent within hours of administration and correlate with plasma concentrations.
Extended-release stimulant formulations offer several advantages for adult patients, including improved medication adherence, reduced stigma associated with workplace dosing, and more consistent symptom control throughout the day. Various delivery mechanisms are employed, including osmotic pump systems (Concerta), capsules containing immediate and delayed-release beads (Adderall XR), and prodrug formulations (Vyvanse). The choice between formulations often depends on individual response patterns, duration of effect requirements, and insurance coverage considerations.
Non-stimulant medications provide alternatives for patients who cannot tolerate stimulants, have contraindications to stimulant use, or prefer non-controlled substances. Atomoxetine (Strattera) is the only FDA-approved non-stimulant medication specifically indicated for adult ADHD. As a selective norepinephrine reuptake inhibitor, atomoxetine provides 24-hour symptom control with once-daily dosing but requires several weeks to achieve full therapeutic effects.
Bupropion, while not FDA-approved for ADHD, is commonly used off-label and demonstrates moderate efficacy in clinical trials. Its dopaminergic and noradrenergic activity provides theoretical rationale for ADHD treatment, and it offers additional benefits for comorbid depression and smoking cessation. Other off-label options include tricyclic antidepressants, though their use is limited by side effect profiles.
Dose optimization requires systematic titration strategies balancing efficacy and tolerability. Starting doses should generally follow manufacturer recommendations, with gradual increases every 1-2 weeks based on symptom response and side effect emergence. The goal is achieving the lowest effective dose that provides meaningful functional improvement. Some patients require doses above typical ranges, while others respond to lower doses.
Side effect management is crucial for maintaining treatment adherence and optimizing outcomes. Common stimulant side effects include appetite suppression, sleep difficulties, cardiovascular effects (increased heart rate and blood pressure), mood changes, and potential for abuse or diversion. Most side effects are dose-related and can be managed through dose adjustment, timing modifications, or adjunctive interventions.
Cardiovascular monitoring is recommended for all patients receiving stimulant medications, though extensive cardiac evaluation is not routinely required for healthy adults. Blood pressure and heart rate should be assessed at baseline and monitored during treatment. Patients with preexisting cardiac conditions may require cardiology consultation and more intensive monitoring.
Psychosocial interventions complement pharmacological treatment and address functional skills deficits that medications alone may not fully remediate. Cognitive-behavioral therapy (CBT) specifically adapted for adult ADHD demonstrates efficacy in randomized controlled trials. CBT interventions focus on developing organizational skills, time management strategies, cognitive restructuring techniques, and relapse prevention approaches.
Coaching has gained popularity as an ADHD-specific intervention focusing on goal-setting, accountability, and skill development. While less research exists on coaching compared to traditional psychotherapy, preliminary studies suggest benefits for functional outcomes and quality of life. Coaching may be particularly valuable for adults with primarily organizational and time management difficulties.
Mindfulness-based interventions show promise for addressing attention difficulties and emotional dysregulation associated with ADHD. Mindfulness meditation practices may improve attention regulation, reduce mind-wandering, and enhance emotional control. These approaches can be integrated with other psychosocial interventions or used as standalone treatments.
Lifestyle modifications can significantly impact ADHD symptoms and overall functioning. Regular aerobic exercise demonstrates benefits for attention, executive function, and mood regulation. Sleep hygiene interventions are crucial given the high prevalence of sleep problems in ADHD. Stress management techniques, organizational systems, and environmental modifications can enhance functional outcomes.
Workplace and academic accommodations represent important non-medical interventions that can substantially improve functional outcomes. Under the Americans with Disabilities Act, adults with ADHD are entitled to reasonable accommodations that enable equal access to employment and educational opportunities. Common accommodations include extended time for tasks, written instructions, reduced distractions, and flexible scheduling.
Treatment monitoring requires systematic assessment of symptom improvement, functional outcomes, and adverse effects. Standardized rating scales can track symptom changes over time, while functional measures assess real-world improvements in work, relationships, and daily activities. Regular follow-up appointments enable ongoing optimization and problem-solving.
Pharmacological Considerations and Clinical Decision-Making
The pharmacological management of adult ADHD requires sophisticated understanding of drug mechanisms, individual response variability, and complex decision-making processes that integrate clinical factors with patient preferences and practical considerations. Contemporary approaches emphasize personalized medicine principles while maintaining evidence-based treatment selection.
Stimulant medication selection involves choosing between methylphenidate-based and amphetamine-based compounds, each with distinct pharmacological profiles. Methylphenidate primarily blocks dopamine reuptake with secondary norepinephrine effects, while amphetamines have more complex mechanisms including reuptake inhibition, release enhancement, and monoamine oxidase inhibition. These mechanistic differences may account for individual response variations, though predicting optimal medication choice remains clinically challenging.
Pharmacokinetic considerations significantly influence treatment outcomes and dosing strategies. Immediate-release stimulants have rapid onset (30-60 minutes) and relatively short duration (3-5 hours), requiring multiple daily doses for sustained effect. Extended-release formulations provide 8-12 hours of symptom control with single daily dosing, improving adherence and reducing workplace stigma. Individual variations in drug metabolism, particularly through cytochrome P450 enzymes, can affect medication efficacy and duration.
Dose-response relationships in adult ADHD demonstrate significant individual variability, necessitating careful titration and monitoring. Some patients achieve optimal response at relatively low doses, while others require higher doses approaching or exceeding manufacturer recommendations. The concept of “optimal dose” encompasses both symptom improvement and functional enhancement while minimizing adverse effects.
Therapeutic drug monitoring is not routinely employed in ADHD treatment but may be valuable in specific circumstances. Plasma concentrations of stimulant medications correlate with clinical effects, though therapeutic ranges are not well-established for routine monitoring. Patients with suboptimal response, suspected adherence issues, or unusual side effect profiles might benefit from concentration measurement.
Side effect profiles vary between stimulant medications and formulations, influencing treatment selection and management strategies. Appetite suppression occurs in 60-80% of patients but often diminishes over time. Sleep disturbances affect 40-60% of patients and can be managed through dose timing adjustments or sleep hygiene interventions. Cardiovascular effects are generally mild but require monitoring, particularly in older adults or those with preexisting cardiac conditions.
Drug interactions with stimulant medications require careful attention, particularly for patients receiving multiple medications. Interactions with monoamine oxidase inhibitors are potentially dangerous and contraindicated. Acidifying agents (ascorbic acid, fruit juices) can reduce stimulant absorption, while alkalinizing agents may enhance absorption. Antacids and proton pump inhibitors can affect extended-release formulation dissolution rates.
Special populations require modified treatment approaches and enhanced monitoring. Older adults may be more sensitive to cardiovascular effects and require lower starting doses with gradual titration. Patients with comorbid cardiovascular disease need careful risk-benefit assessment and possible cardiology consultation. Pregnancy and breastfeeding present complex decision-making scenarios requiring collaboration with obstetric providers.
Non-stimulant alternatives become essential for patients with stimulant contraindications, intolerance, or preference for non-controlled substances. Atomoxetine demonstrates moderate efficacy with different side effect profile, including potential for hepatotoxicity requiring periodic monitoring. Bupropion offers additional benefits for comorbid depression but carries seizure risk in predisposed individuals.
Combination therapy approaches may be beneficial for patients with partial response to monotherapy. Combining stimulants with atomoxetine, antidepressants, or other adjunctive medications can enhance efficacy while managing specific symptom domains. However, combination approaches require careful monitoring for drug interactions and additive side effects.
Treatment resistance scenarios require systematic evaluation and alternative strategies. Factors contributing to apparent treatment failure include inadequate dose, poor adherence, unrecognized comorbidities, or misdiagnosis. Switching between stimulant classes, adjusting formulations, or adding non-stimulant medications may restore therapeutic response.
Long-term treatment considerations encompass safety monitoring, dose adjustments, and periodic treatment evaluation. Current evidence supports long-term stimulant use in adults with appropriate monitoring. Growth concerns relevant in pediatric populations are not applicable to adults, though weight loss and cardiovascular parameters require ongoing attention.
Substance abuse potential represents a legitimate concern requiring balanced clinical judgment. Adults with ADHD have elevated risks for substance use disorders, but appropriately prescribed stimulant medications do not increase these risks and may actually reduce them through symptom improvement. Careful screening, monitoring, and patient education help minimize diversion and abuse risks.
Generic medication considerations affect cost, availability, and potentially clinical response. While generic medications contain identical active ingredients, differences in inactive components or manufacturing processes occasionally affect individual response. Some patients report differences in efficacy or tolerability when switching between generic manufacturers, necessitating brand consistency when possible.
Comorbidity Management and Integrated Care
The management of adult ADHD is complicated by high rates of psychiatric comorbidity, with most adults meeting criteria for at least one additional mental health condition. This comorbidity pattern necessitates integrated treatment approaches that address multiple conditions simultaneously while considering potential interactions between treatments and symptom presentations.
Mood disorders represent the most common comorbid conditions in adult ADHD, with major depressive disorder occurring in 40-50% of cases and bipolar disorder in 15-20% of cases. The relationship between ADHD and mood disorders is complex, involving shared neurobiological pathways, environmental risk factors, and potential causal relationships. Some individuals develop depression secondary to chronic ADHD-related impairments and failures, while others have independently co-occurring conditions.
The differential diagnosis between ADHD and mood disorders requires careful attention to symptom patterns, onset, and course. Both conditions can cause concentration difficulties, but ADHD symptoms are typically present since childhood and consistent across situations, while mood-related concentration problems usually coincide with mood episodes. The presence of anhedonia, hopelessness, and neurovegetative symptoms suggests primary mood disorder, while chronic organizational difficulties and hyperactivity-impulsivity point toward ADHD.
Treatment approaches for comorbid ADHD and depression may involve sequential or simultaneous interventions. Some patients experience mood improvement following effective ADHD treatment, suggesting secondary depression. Others require specific antidepressant treatment alongside ADHD medications. Bupropion offers advantages as a single agent addressing both conditions, while selective serotonin reuptake inhibitors (SSRIs) can be combined safely with stimulants.
Bipolar disorder comorbidity presents particular challenges due to potential mood destabilization from stimulant medications. Adults with ADHD and bipolar disorder typically require mood stabilizer treatment before stimulant initiation. Lamotrigine, lithium, or atypical antipsychotics may provide mood stabilization while potentially offering some benefit for ADHD symptoms. Close monitoring for mood episode precipitation is essential.
Anxiety disorders affect 40-60% of adults with ADHD, with generalized anxiety disorder, social anxiety disorder, and panic disorder being most common. The relationship between ADHD and anxiety is bidirectional, with ADHD symptoms contributing to anxiety development and anxiety interfering with attention and concentration. Stimulant medications may exacerbate anxiety in some patients, necessitating careful monitoring and potential dose adjustments.
Treatment strategies for comorbid anxiety may include non-stimulant ADHD medications for anxious patients, combination therapy with anxiolytics (though benzodiazepines should be used cautiously), or selective serotonin reuptake inhibitors that address both conditions. Cognitive-behavioral therapy techniques can be particularly beneficial for anxiety management in this population.
Substance use disorders occur at rates 2-3 times higher in adults with ADHD compared to the general population. Alcohol use disorders affect 30-40% of adults with ADHD, while cannabis and stimulant use disorders are also elevated. The relationship between ADHD and substance use involves self-medication attempts, impulsivity-driven substance use, and shared genetic vulnerabilities.
The management of comorbid substance use disorders requires careful sequencing of interventions. Active substance abuse typically needs stabilization before ADHD treatment initiation. Non-stimulant medications may be preferred for patients with substance abuse history, though stimulants can be used with appropriate monitoring in stable recovery. Integrated treatment programs addressing both conditions simultaneously show superior outcomes.
Sleep disorders frequently co-occur with ADHD and significantly impact symptom severity and treatment response. Delayed sleep phase syndrome, restless leg syndrome, and sleep-disordered breathing are particularly common. Sleep problems may be primary conditions requiring specific treatment or secondary to ADHD medications. Comprehensive sleep assessment and hygiene interventions are essential components of ADHD management.
Eating disorders, particularly binge eating disorder, occur more frequently in adults with ADHD. The impulsivity and emotional dysregulation associated with ADHD contribute to disordered eating patterns. Stimulant medications’ appetite-suppressing effects may be problematic for patients with eating disorder history, requiring careful monitoring and potentially non-stimulant alternatives.
Learning disabilities often persist alongside ADHD into adulthood, creating cumulative functional impairments. Adults with both conditions may benefit from educational accommodations, vocational training, or specialized therapeutic interventions. Comprehensive assessment should evaluate both attention difficulties and specific learning impairments.
Autism spectrum disorders (ASD) can co-occur with ADHD, though this comorbidity was not recognized in previous diagnostic systems. Adults with both conditions present complex clinical pictures requiring specialized assessment and treatment approaches. Standard ADHD treatments may be effective but require modification for sensory sensitivities and social communication differences.
Personality disorders, particularly borderline and antisocial personality disorders, occur at elevated rates in adults with ADHD. The impulsivity and emotional dysregulation associated with ADHD may contribute to personality disorder development or complicate differential diagnosis. Treatment requires addressing both conditions with specialized therapeutic approaches.
Integrated care models facilitate comprehensive management of complex comorbidity patterns. Collaborative care approaches involving primary care providers, mental health specialists, and other healthcare professionals can improve outcomes while maintaining efficiency. Care coordination, shared treatment planning, and regular communication between providers are essential elements.
Technology Integration and Digital Health Solutions
The integration of digital health technologies into adult ADHD management represents an evolving frontier with significant potential for enhancing assessment accuracy, treatment monitoring, and patient engagement. Contemporary technological solutions range from simple smartphone applications to sophisticated artificial intelligence-driven assessment platforms, each offering unique advantages and limitations for clinical practice.
Electronic health record (EHR) optimization for ADHD care involves developing standardized templates, decision support tools, and monitoring protocols that streamline clinical workflows while ensuring comprehensive documentation. ADHD-specific templates can incorporate validated screening instruments, medication monitoring checklists, and functional outcome measures. Clinical decision support systems can provide dosing recommendations, drug interaction alerts, and guideline-based treatment suggestions.
Mobile health applications for ADHD management have proliferated rapidly, though evidence for their effectiveness remains limited. Symptom tracking applications allow patients to monitor daily ADHD symptoms, medication effects, and functional outcomes. Organizational apps provide task management, scheduling, and reminder systems that address core ADHD-related difficulties. Meditation and mindfulness apps may support attention training and emotional regulation.
Computerized cognitive assessment tools offer standardized approaches to measuring attention, executive function, and other ADHD-related cognitive domains. Continuous performance tests (CPTs) can be administered via computer or tablet platforms, providing objective measures of sustained attention and response inhibition. However, the diagnostic utility of these tools remains controversial due to significant overlap between ADHD and non-ADHD populations.
Wearable devices and sensors represent emerging technologies for objective symptom monitoring. Actigraphy can measure sleep patterns and physical activity levels, providing insights into sleep quality and hyperactivity symptoms. Heart rate variability monitoring may reflect autonomic nervous system function and medication effects. However, the clinical utility of these measures requires further validation.
Telemedicine and virtual care platforms have expanded access to ADHD services, particularly important in underserved geographic regions. Remote consultation capabilities enable specialist input for complex cases, medication management visits, and ongoing monitoring. Structured telehealth protocols can maintain clinical quality while improving accessibility and reducing costs.
Artificial intelligence and machine learning applications in ADHD show promise for enhancing diagnostic accuracy and treatment selection. Natural language processing can analyze clinical notes for ADHD-relevant information, while predictive modeling may identify patients at risk for treatment non-response or adverse events. However, these technologies require extensive validation before clinical implementation.
Digital therapeutics represent a novel category of evidence-based digital interventions designed to treat medical conditions. Several companies have developed digital therapeutic applications specifically for ADHD, incorporating cognitive training exercises, behavioral interventions, and biofeedback components. Regulatory approval processes for these interventions are evolving.
Electronic prescribing systems for controlled substances (EPCS) have become essential for stimulant medication management. These systems improve prescription security, reduce diversion risks, and facilitate monitoring through prescription drug monitoring programs. Integration with EHR systems streamlines clinical workflows while maintaining regulatory compliance.
Patient portal integration enhances communication between patients and providers while supporting self-management activities. Secure messaging systems enable non-urgent clinical communication, medication refill requests, and symptom reporting. Educational resources and self-assessment tools can be delivered through portal platforms.
Virtual reality applications are being explored for ADHD assessment and treatment. VR-based attention tasks may provide more ecologically valid measures of attention function compared to traditional computerized tests. Therapeutic VR applications could deliver immersive cognitive training or mindfulness interventions. However, these technologies remain largely experimental.
Data integration challenges arise when multiple digital health tools are employed simultaneously. Interoperability standards and data sharing protocols are essential for creating comprehensive pictures of patient status and treatment response. Privacy and security considerations become increasingly complex with multiple data streams.
Quality assurance for digital health tools requires evaluation of clinical evidence, regulatory status, and data security measures. Healthcare providers need frameworks for evaluating and recommending digital health solutions to patients. Professional organizations may develop guidelines for digital tool integration in ADHD care.
Future Directions and Emerging Paradigms
The future landscape of adult ADHD management in primary care will be shaped by advancing scientific understanding, technological innovations, and evolving healthcare delivery models. Several key trends and developments are positioned to transform clinical practice and patient outcomes over the coming decades.
Precision medicine approaches represent a fundamental shift toward individualized treatment selection based on patient-specific characteristics. Pharmacogenomic testing may eventually guide medication selection by identifying genetic variants affecting drug metabolism, efficacy, and side effect risk. Current research focuses on cytochrome P450 enzyme variants, dopamine receptor polymorphisms, and other genetic markers that influence treatment response.
Biomarker development continues to advance, with potential applications for both diagnosis and treatment monitoring. Neuroimaging biomarkers, including structural and functional MRI findings, may eventually support objective diagnosis. Blood-based biomarkers, such as inflammatory markers or neurotransmitter metabolites, could provide accessible assessment tools. However, translation from research to clinical application requires extensive validation.
Advanced neurotherapeutic interventions are being investigated for treatment-resistant or severe ADHD cases. Transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) target specific brain regions involved in attention and executive control. Neurofeedback and real-time fMRI training attempt to modify brain activity patterns through operant conditioning principles. These approaches remain largely experimental but show promise for specific populations.
Microbiome research is revealing connections between gut bacteria and neurodevelopmental conditions, including ADHD. The gut-brain axis influences neurotransmitter production, inflammatory responses, and behavior regulation. Future interventions may include targeted probiotic treatments or dietary modifications based on microbiome analysis. This field requires substantial additional research before clinical applications.
Novel pharmacological targets are being explored beyond traditional monoaminergic systems. Glutamate system modulators, such as mGluR5 antagonists, may offer alternative therapeutic approaches. Histamine system modulators and cholinesterase inhibitors are being investigated for cognitive enhancement. These novel mechanisms could provide options for patients who don’t respond to current treatments.
Digital phenotyping involves continuous monitoring of behavior patterns using smartphone sensors, wearable devices, and other passive data collection methods. This approach could provide objective measures of ADHD symptoms and treatment response in real-world settings. Machine learning algorithms could identify subtle changes in activity patterns, sleep quality, or social interactions that reflect clinical status.
Preventive interventions represent an important frontier for reducing ADHD’s long-term impact. Early identification of at-risk children and implementation of protective interventions could prevent or mitigate adult ADHD symptoms. Parenting interventions, educational modifications, and environmental optimizations during critical developmental periods may have lasting effects.
Healthcare delivery model innovations will likely emphasize team-based care, integrated services, and population health approaches. Collaborative care models involving primary care providers, mental health specialists, care managers, and peer support specialists may become standard practice. Value-based payment models could incentivize comprehensive, coordinated care focused on functional outcomes.
Artificial intelligence applications will likely expand beyond diagnostic support to include treatment optimization, adverse event prediction, and personalized intervention recommendations. Natural language processing could analyze clinical documentation to identify optimal treatment candidates. Predictive modeling could anticipate treatment response patterns and guide medication selection.
Regulatory frameworks for digital therapeutics and novel interventions will continue evolving. The FDA has established pathways for digital therapeutic approval, and similar processes are emerging internationally. These frameworks will need to balance innovation with safety while ensuring evidence-based practice standards.
Training and education paradigms for healthcare providers will need updating to incorporate new technologies, treatment approaches, and care delivery models. Competency-based curricula may emphasize ADHD-specific skills, while continuing education programs could provide ongoing updates on emerging interventions. Simulation-based training may enhance clinical decision-making skills.
Patient engagement strategies will likely become more sophisticated, incorporating behavioral economics principles, personalized communication approaches, and peer support networks. Mobile health platforms could deliver just-in-time interventions based on real-time symptom monitoring. Virtual reality could provide immersive educational experiences about ADHD management.
Research priorities should focus on pragmatic clinical questions most relevant to primary care practice. Comparative effectiveness research could identify optimal treatment sequences and combination approaches. Implementation science studies could evaluate strategies for integrating evidence-based practices into routine clinical care. Health economics research could demonstrate the value proposition of comprehensive ADHD management.
Conclusion
The management of adult ADHD in primary care settings represents both a significant opportunity and a complex challenge requiring sophisticated clinical approaches, systematic practice organization, and ongoing professional development. This comprehensive analysis demonstrates that primary care providers can effectively diagnose and treat adult ADHD when equipped with evidence-based assessment tools, pharmacological knowledge, and structured care delivery systems.
The neurobiological foundations of ADHD provide rational targets for pharmacological intervention, with stimulant medications maintaining their position as first-line treatments supported by extensive research evidence. However, the heterogeneity of adult ADHD presentations, high prevalence of comorbid conditions, and individual variations in treatment response necessitate individualized approaches that go beyond simple diagnostic algorithms and standardized treatment protocols.
The diagnostic challenges inherent in adult ADHD assessment, particularly the reliance on retrospective symptom reporting and the absence of definitive biomarkers, underscore the importance of systematic clinical evaluation using validated instruments and structured approaches. Primary care providers must develop competence in differential diagnosis while recognizing the limitations of their assessment and knowing when specialist consultation is appropriate.
The extensive comorbidity patterns observed in adult ADHD, particularly with mood disorders, anxiety disorders, and substance use disorders, require integrated treatment approaches that address multiple conditions simultaneously. This complexity highlights the value of primary care providers who can coordinate comprehensive medical care while maintaining therapeutic relationships that support long-term management.
Technology integration offers significant opportunities for enhancing ADHD care delivery, from electronic health record optimization to digital therapeutic interventions. However, successful implementation requires careful evaluation of evidence, attention to workflow integration, and consideration of patient preferences and digital literacy levels.
The future of adult ADHD management will likely be characterized by increasing precision in treatment selection, enhanced objective monitoring capabilities, and more sophisticated care delivery models that leverage both technological innovations and collaborative care approaches. Primary care providers will need to adapt to these evolving paradigms while maintaining focus on patient-centered care and functional outcome improvement.
Key Takeaways
The management of adult ADHD in primary care requires recognition of several critical principles that distinguish effective from suboptimal care delivery. Understanding these key concepts enables providers to develop systematic approaches that optimize patient outcomes while maintaining feasibility within primary care frameworks.
Adult ADHD represents a prevalent neurodevelopmental condition with significant functional impact that persists from childhood into adulthood, affecting approximately 4-5% of adults worldwide. The condition’s neurobiological basis provides rational targets for pharmacological intervention, while its complex symptom presentations and high comorbidity rates necessitate comprehensive assessment and individualized treatment approaches.
Diagnostic approaches must be systematic and evidence-based, incorporating validated assessment instruments while recognizing the limitations of retrospective symptom reporting and the absence of objective biomarkers. Primary care providers should develop competence in differential diagnosis, functional impairment assessment, and recognition of comorbid conditions while knowing when specialist consultation is appropriate.
Pharmacological treatment with stimulant medications remains the most effective intervention for adult ADHD, with careful attention to dose optimization, side effect management, and long-term monitoring. Non-stimulant alternatives provide options for patients with contraindications or preferences for non-controlled substances, while combination approaches may benefit patients with partial response to monotherapy.
Comorbidity management requires integrated approaches that address multiple conditions simultaneously rather than sequential treatment of individual disorders. Depression, anxiety disorders, and substance use disorders occur at elevated rates and significantly impact treatment planning and outcomes.
Patient communication and engagement strategies must account for ADHD-related attention difficulties, organizational problems, and potential histories of negative healthcare experiences. Building therapeutic relationships based on understanding and support rather than judgment is essential for treatment adherence and long-term success.
Long-term management approaches should emphasize functional outcome improvement rather than simply symptom reduction, with regular monitoring of occupational, social, and academic functioning. Treatment goals should be individualized and realistic, with recognition that ADHD is a chronic condition requiring ongoing support and adjustment.
System-level considerations including practice organization, care coordination, and quality improvement initiatives can enhance ADHD care delivery while addressing common barriers such as time constraints, documentation requirements, and insurance authorization processes.
Future developments in precision medicine, digital health technologies, and care delivery models will likely enhance ADHD management capabilities while requiring ongoing provider education and adaptation. Staying current with emerging evidence and maintaining focus on patient-centered care will be essential for optimal practice evolution.
Frequently Asked Questions:
What distinguishes adult ADHD from normal attention difficulties or stress-related concentration problems?
Adult ADHD is characterized by persistent symptoms that began in childhood (before age 12) and cause significant functional impairment across multiple life domains. Unlike stress-related attention problems, ADHD symptoms are consistent across different situations and time periods, not limited to periods of high stress or life transitions. The symptoms represent a persistent pattern rather than episodic difficulties, and they typically interfere with work, relationships, and daily functioning in ways that exceed normal variations in attention and organization.
How reliable are self-report screening instruments for adult ADHD diagnosis?
Self-report instruments like the ASRS are valuable screening tools but cannot definitively diagnose ADHD. They demonstrate good sensitivity for identifying potential cases but have limitations in specificity, meaning some individuals without ADHD may score positive. These tools should be used as part of comprehensive clinical evaluation including structured interview, functional assessment, and consideration of differential diagnosis. They are most useful for initial screening and ongoing symptom monitoring rather than standalone diagnostic decisions.
What evidence supports the long-term safety of stimulant medications in adults?
Current evidence supports the long-term safety of stimulant medications in adults when appropriately prescribed and monitored. Longitudinal studies have not identified significant risks of cardiac events, dependence, or other serious adverse outcomes in properly screened patients. However, ongoing monitoring of cardiovascular parameters, weight, and mental health status is recommended. The benefits of treatment typically outweigh risks for most adults with clinically significant ADHD, though individual risk-benefit calculations should guide treatment decisions.
How should comorbid substance use disorders affect ADHD treatment decisions?
Active substance use disorders generally require stabilization before initiating ADHD treatment, though integrated approaches addressing both conditions simultaneously may be optimal. For patients with remote substance use history in stable recovery, stimulant medications can often be used safely with appropriate monitoring and coordination with addiction treatment providers. Non-stimulant medications may be preferred in some cases, though they should not be automatically chosen based solely on substance use history if clinical indicators support stimulant treatment.
What role should neuropsychological testing play in adult ADHD assessment?
Neuropsychological testing is not required for ADHD diagnosis and cannot definitively confirm or rule out the condition due to significant overlap between ADHD and non-ADHD populations on cognitive measures. Testing may be helpful for identifying specific cognitive strengths and weaknesses, planning accommodations, or evaluating for learning disabilities. However, it should supplement rather than replace clinical interview and functional assessment. The decision to pursue testing should be based on specific clinical questions rather than routine diagnostic protocol.
How can primary care providers effectively manage medication titration and monitoring?
Effective medication management requires systematic approaches including standardized starting protocols, regular follow-up scheduling, and consistent monitoring parameters. Providers should establish clear titration schedules (typically every 1-2 weeks during initial phases), use standardized assessment tools to track response, and maintain consistent documentation of efficacy and side effects. Developing relationships with pharmacists and mental health specialists for consultation support enhances clinical confidence and patient safety.
What accommodations are commonly needed by adults with ADHD in workplace settings?
Common workplace accommodations include written instructions rather than verbal directions alone, flexible scheduling to accommodate peak attention periods, reduced environmental distractions, extended deadlines when feasible, and regular check-ins with supervisors. The specific accommodations should be individualized based on job requirements and individual symptom patterns. Primary care providers can support accommodation requests by providing documentation of functional limitations without requiring extensive disability evaluations.
How should treatment goals be established and monitored for adults with ADHD?
Treatment goals should be individualized and focus on functional improvements rather than simply symptom reduction. Common goal areas include occupational performance, interpersonal relationships, educational achievement, and daily life management. Goals should be specific, measurable, and realistic, with regular reassessment to track progress and adjust expectations. Using standardized functional outcome measures can provide objective monitoring while patient self-report provides subjective quality of life assessment.
When should primary care providers refer adults with ADHD to specialists?
Specialist referral should be considered for complex comorbidity patterns, treatment-resistant cases, diagnostic uncertainty, or when provider comfort level is exceeded. Specific indications include suspected bipolar disorder, active psychosis, severe substance use disorders, multiple failed medication trials, or requests for complex medication combinations. Geographic availability of specialists may influence referral thresholds, but providers should maintain clear criteria for when additional expertise is needed.
What emerging treatments show promise for adult ADHD management?
Emerging treatments include novel pharmacological targets (glutamate modulators, histamine system agents), non-invasive brain stimulation techniques (TMS, tDCS), digital therapeutics incorporating cognitive training or biofeedback, and personalized medicine approaches based on genetic testing. However, most of these interventions remain experimental and require additional research before clinical implementation. Providers should focus on optimizing established treatments while staying informed about emerging options through continuing education and professional literature.
References:
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Publishing.
Asherson, P., Akehurst, R., Kooij, J. J. S., Huss, M., Beusterien, K., Sasané, R., … & Hodgkins, P. (2012). Under-diagnosis of adult ADHD: Cultural influences and societal burden. Journal of Attention Disorders, 16(5 Suppl), 20S-38S.
Barkley, R. A., Murphy, K. R., & Fischer, M. (2008). ADHD in adults: What the science says. Guilford Press.
Biederman, J., Faraone, S. V., Spencer, T. J., Mick, E., Monuteaux, M. C., & Aleardi, M. (2006). Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community. Journal of Clinical Psychiatry, 67(4), 524-540.
Canadian ADHD Resource Alliance. (2018). Canadian ADHD practice guidelines (4th ed.). CADDRA.
Cortese, S., Kelly, C., Chabernaud, C., Proal, E., Di Martino, A., Milham, M. P., & Castellanos, F. X. (2012). Toward systems neuroscience of ADHD: A meta-analysis of 55 fMRI studies. American Journal of Psychiatry, 169(10), 1038-1055.
Faraone, S. V., Asherson, P., Banaschewski, T., Biederman, J., Buitelaar, J. K., Ramos-Quiroga, J. A., … & Franke, B. (2015). Attention-deficit/hyperactivity disorder. Nature Reviews Disease Primers, 1, 15020.
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., … & Zaslavsky, A. M. (2006). The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. American Journal of Psychiatry, 163(4), 716-723.
Kooij, S. J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P. J., … & Asherson, P. (2010). European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry, 10, 67.
National Institute for Health and Care Excellence. (2018). Attention deficit hyperactivity disorder: diagnosis and management (NICE guideline NG87). NICE.
Ramos-Quiroga, J. A., Montoya, A., Kutzelnigg, A., Deberdt, W., Sobanski, E., Battino, N., … & Casas, M. (2013). Time to response following treatment initiation with methylphenidate or atomoxetine in children and adolescents with ADHD. CNS Drugs, 27(8), 617-627.
Safren, S. A., Sprich, S., Mimiaga, M. J., Surman, C., Knouse, L., Groves, M., & Otto, M. W. (2010). Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: A randomized controlled trial. JAMA, 304(8), 875-880.
Simon, V., Czobor, P., Bálint, S., Mészáros, A., & Bitter, I. (2009). Prevalence and correlates of adult attention-deficit hyperactivity disorder: Meta-analysis. British Journal of Psychiatry, 194(3), 204-211.
Weiss, M., Safren, S. A., Solanto, M. V., Hechtman, L., Rostain, A. L., Ramsay, J. R., & Murray, C. (2008). Research forum on psychological treatment of adults with ADHD. Journal of Attention Disorders, 11(6), 642-651.
Wolraich, M. L., Hagan Jr, J. F., Allan, C., Chan, E., Davison, D., Earls, M., … & Zurhellen, W. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 144(4), e20192528.
